Journal article
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: Results from the CAVALLI phase 1b trial
AD Zelenetz, G Salles, KD Mason, C Casulo, S Le Gouill, LH Sehn, H Tilly, G Cartron, MED Chamuleau, A Goy, CS Tam, PJ Lugtenburg, AM Petrich, A Sinha, D Samineni, S Herter, E Ingalla, E Szafer-Glusman, C Klein, D Sampath Show all
Blood | Published : 2019
Abstract
Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Objectives included safety assessment and determination of a recommended phase 2 dose (RP2D). Fifty-six patients were enrolled, most with follicular lymphoma (43%) or diffuse large B-cell lymphoma (DLBCL; 32%). Dose-limiting toxicities were reported in 3/14 patients ..
View full abstractGrants
Funding Acknowledgements
Venetoclax is being developed in collaboration between Genentech Inc and AbbVie. Genentech and AbbVie provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review, and approval of the manuscript. Medical writing support was provided by Tara Miller of Envision Pharma Group and Kate Rijnen of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche Ltd.